Tectorigenin

Tectorigenin blocks NF-κB activation and MAPK (ERK/JNK/p38) phosphorylation, lowering iNOS/COX-2, TNF-α, IL-6 and IL-1β across models: fulminant hepatic failure (TLR4/NF-κB and TLR4/MAPK, with autophagy) ^{4Reference 4Zhang L et al. · 2019Tectorigenin protects against experimental fulminant hepatic failure by regulating the TLR4/MAPK and TLR4/NF-κB pathways and autophagyView study →}, murine inflammatory bowel disease and LPS macrophages ^{5Reference 5Huang H et al. · 2024AnimalTectorigenin inhibits inflammatory responses in murine inflammatory bowel disease and LPS-stimulated macrophages via inactivating MAPK signallingView study →}, BV-2 microglial neuroinflammation ^{6Reference 6Lim HS et al. · 2018The anti-neuroinflammatory activity of tectorigenin via downregulated NF-κB and ERK/JNK pathways in BV-2 microgliaView study →} and TNF-α-stimulated tendon-derived stem cells ^{7Reference 7Moqbel SAA et al. · 2020AnimalTectorigenin alleviates inflammation, apoptosis and ossification in rat tendon-derived stem cells via modulating NF-κB and MAPK pathwaysView study →}; the I. tectorum rhizome extract shows the same NF-κB inhibition ^{13Reference 13Guo YL et al. · 2026Iris tectorum rhizome alleviates LPS-triggered inflammatory responses through inhibiting NF-κB signalling in macrophagesView study →}.

Gap: entirely preclinical, with unestablished human-achievable concentrations, and the rhizome-extract study is not isolate-specific ^{4,13Reference 4Zhang L et al. · 2019Tectorigenin protects against experimental fulminant hepatic failure by regulating the TLR4/MAPK and TLR4/NF-κB pathways and autophagyView study →Reference 13Guo YL et al. · 2026Iris tectorum rhizome alleviates LPS-triggered inflammatory responses through inhibiting NF-κB signalling in macrophagesView study →}.

The compound’s more distinctive signal. In high-fat-diet NAFLD, tectorigenin suppressed lipogenesis (↓ SREBP-1c, ↓ FAS) and promoted fatty-acid oxidation (↑ PPARα, ↑ CPT-1) alongside anti-inflammation and gut-microbiota modulation ^{2Reference 2Duan R et al. · 2022AnimalTectorigenin ameliorated high-fat-diet-induced non-alcoholic fatty liver disease through anti-inflammation and modulating gut microbiota in miceView study →}; in diabetic nephropathy it improved vascular endothelial function via the adiponectin AdipoR1/2 pathway ^{3Reference 3Yang S et al. · 2020Tectorigenin attenuates diabetic nephropathy by improving vascular-endothelium dysfunction through activating the AdipoR1/2 pathwayView study →}.

Gap: only two rodent models with no human data, and the PPARα engagement is inferred from expression changes rather than direct receptor binding ^{2,3Reference 2Duan R et al. · 2022AnimalTectorigenin ameliorated high-fat-diet-induced non-alcoholic fatty liver disease through anti-inflammation and modulating gut microbiota in miceView study →Reference 3Yang S et al. · 2020Tectorigenin attenuates diabetic nephropathy by improving vascular-endothelium dysfunction through activating the AdipoR1/2 pathwayView study →}.

Tectorigenin activates the Keap1/Nrf2/HO-1 axis to blunt oxidative stress in Th2-mediated allergic asthma ^{8Reference 8Jiang Y et al. · 2024AnimalTectorigenin inhibits oxidative stress by activating the Keap1/Nrf2/HO-1 pathway in Th2-mediated allergic asthmatic miceView study →} and, with FXR modulation, against ANIT-induced cholestatic liver injury ^{9Reference 9Cao P et al. · 2023Molecular mechanisms of the hepatoprotective effect of tectorigenin against ANIT-induced cholestatic liver injury: role of FXR and Nrf2View study →}.

Gap: preclinical, and largely a shared isoflavone-class cytoprotective effect rather than tectorigenin-unique ^{8,9Reference 8Jiang Y et al. · 2024AnimalTectorigenin inhibits oxidative stress by activating the Keap1/Nrf2/HO-1 pathway in Th2-mediated allergic asthmatic miceView study →Reference 9Cao P et al. · 2023Molecular mechanisms of the hepatoprotective effect of tectorigenin against ANIT-induced cholestatic liver injury: role of FXR and Nrf2View study →}.

Phytoestrogens from Belamcanda chinensis (a tectorigenin/tectoridin source) modulated steroid-receptor and cofactor expression in LNCaP prostate cancer cells ^{10Reference 10Thelen P et al. · 2007Phytoestrogens from Belamcanda chinensis regulate the expression of steroid receptors and related cofactors in LNCaP prostate cancer cellsView study →}, and tectorigenin induced estrogen-receptor-dependent vasorelaxation in porcine coronary arteries ^{11Reference 11Chen TY et al. · 2025Tectorigenin induces vasorelaxation in porcine coronary arteries through activation of Kv channels and estrogen-receptor modulationView study →}; a 2026 review catalogues broader antiproliferative signals ^{1Reference 1Zhang S et al. · 2026ReviewFrom nature to pharmacy: a review of tectoridin for modern therapeuticsView study →}.

Gap: thin — largely a fraction (not pure isolate) in one cell line, with no in-vivo tumor efficacy or clinical signal, and the ER activity is modest ^{10,11Reference 10Thelen P et al. · 2007Phytoestrogens from Belamcanda chinensis regulate the expression of steroid receptors and related cofactors in LNCaP prostate cancer cellsView study →Reference 11Chen TY et al. · 2025Tectorigenin induces vasorelaxation in porcine coronary arteries through activation of Kv channels and estrogen-receptor modulationView study →}.